



# Expression of TRAIL, IP-10, and CRP in children with suspected COVID-19 and real-life impact of a computational signature on clinical decision-making: a prospective cohort study

Franziska Fröhlich<sup>1,2</sup> · Benjamin Gronwald<sup>2</sup> · Johannes Bay<sup>2</sup> · Arne Simon<sup>3</sup> · Martin Poryo<sup>4</sup> · Jürgen Geisel<sup>5</sup> · Sina A. Tegethoff<sup>1</sup> · Katharina Last<sup>1,6</sup> · Jürgen Rissland<sup>7</sup> · Sigrun Smola<sup>7,8</sup> · Sören L. Becker<sup>1</sup> · Michael Zemlin<sup>2</sup> · Sascha Meyer<sup>2</sup> · Cihan Papan<sup>1,6</sup>

Received: 2 December 2022 / Accepted: 28 January 2023 / Published online: 9 February 2023  
© The Author(s) 2023

## Abstract

**Purpose** We evaluated the host-response marker score “BV” and its components TRAIL, IP-10, and CRP in SARS-CoV-2 positive children, and estimated the potential impact on clinical decision-making.

**Methods** We prospectively analyzed levels of TRAIL, IP-10, CRP, and the BV score, in children with suspected COVID-19. Classification of infectious etiology was performed by an expert panel. We used a 5-point-questionnaire to evaluate the intention to treat with antibiotics before and after receiving test results.

**Results** We screened 111 children, of whom 6 (5.4%) were positive for SARS-CoV-2. A total of 53 children were included for the exploratory analysis. Median age was 3.1 years (interquartile range [IQR] 1.3–4.3), and 54.7% ( $n=29$ ) were girls. A viral and a bacterial biomarker pattern was found in 27/53 (50.9%) and 15/53 (28.3%), respectively. BV scores differed between COVID-19, children with other viral infections, and children with bacterial infections (medians 29.5 vs. 9 vs. 66;  $p=0.0006$ ). Similarly, median TRAIL levels were different (65.5 vs. 110 vs. 78;  $p=0.037$ ). We found no differences in IP-10 levels (555 vs. 504 vs. 285;  $p=0.22$ ). We found a concordance between physicians’ “unlikely intention to treat” children with a viral test result in most cases ( $n=19/24$ , 79.2%). When physicians expressed a “likely intention to treat” ( $n=15$ ), BV test revealed 5 bacterial, viral, and equivocal scores each. Antibiotics were withheld in three cases (20%). Overall, 27/42 (64%) of pediatricians appraised the BV test positively, and considered it helpful in clinical practice.

**Conclusion** Host-response based categorization of infectious diseases might help to overcome diagnostic uncertainty, support clinical decision-making and reduce unnecessary antibiotic treatment.

**Keywords** COVID-19 · Antimicrobial stewardship · Children · Emergency department · Clinical decision-making · Biomarkers · C-reactive protein · TRAIL protein · IP-10 protein

Sascha Meyer and Cihan Papan have contributed equally.

✉ Cihan Papan  
cihan.papan@uni-saarland.de

<sup>1</sup> Center for Infectious Diseases, Institute of Medical Microbiology and Hygiene, Saarland University, Kirrberger Strasse, Building 43, Homburg, Germany

<sup>2</sup> Department of General Pediatrics and Neonatology, Saarland University Hospital, Homburg, Germany

<sup>3</sup> Department of Pediatric Hematology and Oncology, Saarland University Hospital, Homburg, Germany

<sup>4</sup> Department of Pediatric Cardiology, Saarland University Hospital, Homburg, Germany

<sup>5</sup> Department of Clinical Chemistry and Laboratory Medicine, Saarland University Medical Centre, Saarland University Hospital, Homburg, Germany

<sup>6</sup> Institute for Hygiene and Public Health, University Hospital Bonn, Bonn, Germany

<sup>7</sup> Institute of Virology, Saarland University Medical Center, Homburg, Germany

<sup>8</sup> Helmholtz Center for Infection Research (HZI), Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Saarland University Campus, Saarbrücken, Germany

## Introduction

Over- and misuse of antibiotics is a major concern in pediatric cohorts and drives emergence of antimicrobial resistance (AMR) as well as individual side effects, including alterations of the microbiome [1–3]. Prudent antibiotic use is promoted by knowledge of whether an infection is present, as well as identification of its etiology [4]. However, diagnostic uncertainty in particular concerning the question whether the infection is viral or bacterial in origin, remains high among pediatric practitioners, especially when diagnosis is based solely on clinical judgment [5]. This challenge has persisted throughout the COVID-19 pandemic [6, 7], with clinical manifestations of pediatric SARS-CoV-2 infection ranging from upper respiratory infection to severe inflammatory states, including multisystem inflammatory syndrome in children (MIS-C) [8]. In addition, point-of-care screening tools such as rapid SARS-CoV-2 antigen tests have yielded low sensitivities for children [9].

Several studies have shown that host-protein biomarkers are promising tools for both detection and differentiation of bacterial and viral infections [10, 11]. A novel immunoassay combines measurements of TNF-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP-10), and C-reactive protein (CRP) to generate a score (BV). With a negative predictive value of 98.9%, the score has promise to be valuable in reducing antibiotic overuse in viral infections [12]. In addition, newer data suggest that TRAIL correlates with clinical severity in children with respiratory tract infections [13]. Of note, studies on other biomarker combinations, e.g., CRP and myxovirus resistance protein A, have shown promising results in regard to screening for COVID-19 and triaging in the emergency department (ED) [14, 15].

Here, we (i) analyzed the BV score and its three constituent biomarkers in SARS-CoV-2 infected children, in comparison with other viral and bacterial infections, presenting to a University Medical Center; this is a subgroup analysis of the previously reported DIRECTOR study [16].

Furthermore, we (ii) evaluated the BV score as an additional tool in the pediatric ED as an exploratory endpoint, and report on the physicians' assessments of the associated potential for improvement in clinical practice, particularly in antibiotic prescribing.

## Methods

Between November 2020 and August 2021, children and adolescents aged > 90 days with symptoms of a respiratory tract infection or fever without an apparent focus,

compatible with COVID-19, were recruited at Saarland University Children's Hospital in Homburg, Germany. The study was approved by the Ethics committee of the Ärztekammer des Saarlandes (reference number 019/20).

As standard of care, every patient received a nasopharyngeal swab which was tested via polymerase chain reaction for the presence of SARS-CoV-2. In addition, a multiplex PCR was performed to test for several respiratory viruses and bacteria. The multiplex panel (FTD Respiratory pathogens 21, Siemens Healthineers) included the following pathogen detections: influenza A; influenza A/H1N1; influenza B; parainfluenza types 1, 2, 3, 4; coronavirus NL63, 229E, OC43, HKU1; human metapneumovirus (A/B); human bocavirus; rhinovirus; adenovirus; respiratory syncytial virus (A/B); parechovirus; enterovirus and *Mycoplasma pneumoniae*. This commercial, real-time PCR assay was performed according to the manufacturer's instructions and as previously described [17]. Bacterial infections were confirmed by bacteriologic cultures of blood, throat swabs, or other clinical samples.

According to the results and in due consideration of all patient data, we divided the cohort into three groups: patients with COVID-19, patients with other viral respiratory tract infection, and patients with bacterial infection.

We measured TRAIL, IP-10 and CRP and calculated the corresponding BV score by placing 100 µL of patients' serum in a MeMed BV<sup>®</sup> cartridge and running the test on MeMed Key<sup>®</sup> (MeMed; Tirat Carmel, Israel) as described previously [16, 18]. For this purpose, an additional serum tube was collected during routinely performed blood draws. The resulting BV score ranges between 0 and 100 and defines infectious etiology as viral (0–34), equivocal (35–65) or bacterial (66–100). We compared the BV score's alignment with infectious disease etiology in comparison with CRP, for which we used CRP bins of < 20 mg/L (indicating viral etiology), 20–80 mg/L (inconclusive), and > 80 mg/L (bacterial), based on previous literature [19]. For statistical analyses, we used Kruskal–Wallis tests and pair-wise Wilcoxon rank sum tests with Bonferroni correction, using RStudio (Version 2022.07.1 + 554).

For the exploratory endpoint, we handed a 5-point questionnaire to ED physicians, which contained questions about their intention to initiate antibiotic therapy (before and after receiving test results); furthermore, we asked physicians if the test result, which was accessible to the physician, influenced their clinical decision-making.

Three pediatricians, each with more than 10 years of work experience, formed an expert panel and evaluated each patient's disease etiology (before and after receiving test results) while blinded for each other's adjudication, as described previously [12]. Majority voting of the expert

panel was used as additional classification. Of note, none of the experts was involved in the patients' care.

## Results

### Study population

Out of 111 children screened in our pediatric ED for possible SARS-CoV-2 infection, 6 children (5.4%) tested positive for SARS-CoV-2 (COVID-19 group), one of whom was diagnosed with MIS-C. The median age of the COVID-19 group was 9.3 years (IQR 4–13.2), and 50% ( $n=3$ ) were girls. Among the 111 patients, 53 fell within the original instructions for use of the BV. The median age of this exploratory study cohort ( $n=53$ ) was 3.1 years (interquartile range [IQR] 1.3–4.3) and 29 (54.7%) were girls. The viral (non-COVID-19) group consisted of 27 children (50.9%), in which 15 were girls (55.6%) and the median age was 1.7 years (IQR 1.2–3.3). Bacterial infection (bacterial group) was diagnosed in 15 patients (28.3%) with a median age of 3.5 years (IQR 1.2–4.5), including 9 girls (60%).

### Results of biomarker measurements

In the COVID-19 group, there was a median BV score of 29.5 (IQR 8–41.3) and a median TRAIL level of 65.5 pg/mL (IQR 42–167) (Table 1). IP-10 levels showed a median of 555 pg/mL (IQR 336–2117.3) and CRP levels reached a median of 19.5 mg/L (IQR 2–42.2). The child with MIS-C (with positive SARS-CoV-2 PCR) showed a BV score of 100. The TRAIL level was 19 pg/mL, IP-10 yielded a level of higher than 6000 pg/mL and the value of CRP was 196.9 mg/L (Table 1).


The median BV score in the viral (non-COVID-19) group was 9 (IQR 0–25.5), whereas the median levels for the individual biomarkers were as follows: TRAIL 110 pg/mL (IQR 79.5–245.5), IP-10 504 pg/mL (IQR 316.5–813), and CRP 12.3 mg/L (IQR 3.7–26.9).

Patients with bacterial infections yielded a median score of 66 (IQR 22–81.5). The median measurements for TRAIL, IP-10 and CRP were 78 pg/mL (IQR 48–105.5), 285 pg/mL (IQR 209–507), and 82.8 mg/L (IQR 34.9–119), respectively (Fig. 1).

BV scores differed significantly between the three groups COVID-19, children with other viral infections, and children with bacterial infections ( $p=0.0006$ ). The difference was significant in pair-wise comparison for viral vs. bacterial groups ( $p=0.0003$ ), while there was no difference between

**Table 1** Demographic and biomarker data of the COVID-19 cases within the cohort; age in years; F: female, M: male

	Age	Sex	Test IFU fulfilled	BV score	TRAIL (pg/mL)	CRP (mg/L)	IP-10 (pg/mL)	Comment
KK005	6.9	F	Yes	100	19	196.9	6001	MIS-C
KK012	3.1	M	Yes	1	200	6.3	320	
KK024	2.5	F	No	0	301	0.5	726	
KK026	22.9	F	No	29	35	0.5	99	
KK035	13.7	M	Yes	45	68	45.7	384	
KK062	11.6	M	No	30	63	32.6	2581	




**Fig. 1** Comparison of TRAIL, IP-10, CRP and BV score, among the three subgroups (median marked with red line)

COVID-19 and the viral or bacterial groups ( $p=0.69$  and  $p=0.78$ ). Similarly, median TRAIL levels were significantly different over all groups ( $p=0.037$ ), with the difference between viral and bacterial being significant ( $p=0.035$ ), and no difference between COVID-19 and the two other groups

( $p=0.67$  and  $p=1.0$ ). We found no significant differences in IP-10 levels ( $p=0.22$ ).

When comparing the BV score to CRP levels to categorize diseases' etiology, the score indicated an equivocal result in 11 cases, whereas inconclusive levels of CRP (20–80 mg/L) appeared in 19 patients (Fig. 2).




**Fig. 2** Comparison of categorizing disease etiology by BV and CRP (mg/L); BV 0–34: viral etiology, BV 35–65 equivocal etiology, BV 66–100 bacterial etiology;  $n=53$

**Potential impact of the BV score on clinical decision-making**

After initial physical examination, ED physicians stated that they were unlikely to treat the patients with antibiotics in 24/53 cases (45.3%). Among these patients, the BV score indicated a bacterial infectious etiology for 2/24 (8.3%) and a viral etiology for 19/24 (79.2%) of the patients. Three of the 24 cases yielded equivocal BV scores. Upon receiving these results, the physicians changed their mind regarding one patient (equivocal) and initiated an antibiotic therapy (Fig. 3).

Although ED doctors initially did not intend to prescribe antibiotics for the two children with bacterial BV scores, antibiotics were prescribed during their hospital stay. Experts considered those cases to be of viral and non-infectious origin. Overall, our expert panel aligned with the score's result in 17 out of 24 cases (70.8%).

When physicians stated they were uncertain whether to prescribe antibiotics after initial examination (“no statement”,  $n=14$ ), they did not prescribe antibiotics in 6/8 cases with a viral BV result. A bacterial result ( $n=3$ , 21.4%) prompted them to consider antibiotic therapy in two cases (Fig. 3). Pediatricians refused to prescribe antibiotics for one



**Fig. 3** Intention to prescribe antibiotics before and after BV result (\* already treated with antibiotics, prescribed by family pediatrician); *abx* antibiotics

bacterial case, in whom *Campylobacter* spp. was detected in stool. Experts assumed viral origin in this case. Across all 14 ‘no statement’ cases, our experts identified 9 viral infections and one bacterial infection. One case was considered to be indeterminable. There was no agreement for 3 cases. After initial physical examination, ED physicians stated that they were likely to prescribe antibiotics for 15/53 patients (28.3%). The BV score indicated a bacterial, equivocal, and viral origin in an equal measure in this group ( $n=5$ , respectively). Knowledge of the score resulted in withholding of antibiotics in 3/15 (20%) cases (Fig. 3). A follow-up interview did not reveal any unfavorable outcome for those three patients, and they all did well after being discharged. Experts and medical files confirmed the viral results in two cases and notably, antibiotics were not prescribed. However, for one patient, antibiotic treatment became necessary during their hospital stay. (Fig. 3; Table 2).

Overall, experts aligned with BV results in 9/15 cases (64.3%). Of note, when assessing the entire hospital stay of the 53 patients, antibiotic treatment rates were higher than the rate derived from the physician’s responses via questionnaire (47.2% prescriptions in total cohort,  $n=25$ ). Based on their responses in the questionnaire, 27 of the 42 treating physicians (64%) considered the BV score to be a helpful tool in clinical practice: this includes confirming their treatment decision ( $n=22$ , 52%) as well as changing therapy regimen (12%). In 15 instances (36%), pediatricians reported that the tool was no help in clinical decision-making. This impression of the BV test’s utility was mostly shared by our expert panel: positive feedback (confirming decisions, changing therapy regimen) was stated for 67.9%, 45.3%, and 69.8% of the cases by the three senior physicians, respectively.

## Discussion

In this study, we showed no statistically significant difference in host-response biomarker expressions and the BV score for children with SARS-CoV-2 infections as compared to children with other viral or bacterial infections, mainly due to the small sample size. Of note, our cohort included a patient with MIS-C, whose particular biomarker expression was most likely caused by an immune dysregulation reminiscent of critical adult COVID-19 [16].

Although there is only one case described, testing for MIS-C via host-response biomarkers may pose a promising tool: diagnosing MIS-C can be challenging and is mostly based on exclusion of other diseases [20, 21]. Revealing MIS-C via blood test and biomarker constellation might shorten the time to diagnosis.

We observed that utilization of the BV score in a pediatric ED guides clinical decision-making and improves

the appropriate use of antibiotics. As it was mentioned by pediatricians themselves, the tool offers guidance and might help to overcome diagnostic uncertainty. The low turnaround time of one hour also contributes to a short time to treatment, which is associated with lower mortality [22].

Interestingly, BV scores were less often equivocal than CRP yielded inconclusive values between 20 and 80 mg/L. This is of particular importance, since the clinical utility of CRP in particular in an early stage of the infection is often hampered by this area of uncertainty in which CRP offers inferior diagnostic accuracy with respect to detecting serious bacterial infections in children [19].

Knowledge of the score’s result led to rethinking among practitioners and lowered prescription rates when the test revealed a viral infectious etiology. The fact that our expert panel’s opinion was aligned to the score’s group assignment in most cases supports its diagnostic accuracy. These real-world data support the clinical value of the BV test when there is diagnostic uncertainty at the patient’s first assessment.

Both, practitioners and experts, reported very positively about the use of the test, especially in the dilemma of diagnostic uncertainty, where confirming results are desperately needed.

Limitations of our study were the small study size and the monocentric design which made it only possible to show trends in biomarker expression. A larger, multicentric validation study would be necessary before considering the use of this test to screen for children with COVID-19 or with complications such as MIS-C. Based on real-life conditions, which was one of the aims of the study, the subgroup of COVID-19 positive children was highly heterogeneous. This may have been caused by the small number, including one rare case of MIS-C with significantly different biomarker levels. A more homogenous COVID-19 cohort might have yielded more specific results.

Also of note, the score cannot identify non-infectious diseases, such as autoimmune or other disorders, whereas the expert panel was given that option in their assessment. Perhaps the confirmation rate would have been higher otherwise. Moreover, knowledge of infectious etiology is not the only factor influencing clinical decision-making, and other factors can contribute to a lack of guideline adherence [23, 24]. However, obtaining and qualitatively assessing physicians’ rationale to treat or withhold antibiotics was beyond the scope of our study.

In conclusion, the BV score showed potential to be implemented into routine diagnostics in pediatric EDs. Therefore, large prospective studies are needed to confirm our results. The goal should be to create treatment algorithms following the test’s categorizations to improve clinical practice and help counteract the spread of AMR.

**Table 2** Intention and real-life antibiotic prescription during hospital stay: demographics, pediatricians' and experts' assessment compared to BV result and lab data; age in years

Age	Sex	Days from symptom onset	Questionnaire: Intent to Prescribe Abx before test result	BV	CRP	WBC	Questionnaire: intent to prescribe Abx after test result	Real-life data: Abx prescribed (Medical file)	Microbiology	Discharge diagnosis	Experts' vote
1.6	F	2	Probable	9	12.2	6.9	Not prescribed	-	Urine culture: <i>Proteus mirabilis</i> , < 10 <sup>3</sup> /mL	Febrile upper respiratory tract infection	Viral
1	M	0	Probable	0	2.9	11.5	Not prescribed	-	Nasopharyngeal swab: Coronavirus NL63	Febrile upper respiratory tract infection	Viral
2.3	F	1	No statement	66	72.3	10.1	Not prescribed	-	Stool: <i>Campylobacter jejunicoli</i>	1st febrile seizure, gastroenteritis [Bacterial etiology]	Viral
3.4	F	1	No statement	29	78.7	13.6	Prescribed (and then canceled)	Yes	-	Suspected periodic fever, suspected febrile seizure	No agreement
4.4	M	3	No statement	33	14.3	9.7	Prescribed	Yes	Nasopharyngeal swab: <i>Streptococcus pneumoniae</i> RSV	first day: presented under antibiotics, positive rapid strep-test; third day: negative culture; fourth day: Abx stopped, bronchitis	Viral
6.9	F	4	Unlikely	100	198.8	12.5	Not prescribed	Yes	Throat swab: <i>Staphylococcus aureus</i>	MISC: Multisystem Inflammatory Syndrome in Children, cardiac involvement after SARS-CoV-2 infection	Non-infectious
5	F	2-3	Very unlikely	78	12.9	19.6	Not prescribed	Yes	Urine culture - Positive, CFU < 10 <sup>3</sup> /mL	Rhabdomyolysis, suspected myocarditis [Indeterminate etiology]	Viral

Abx antibiotics, CFU colony-forming units, CRP C-reactive protein (mg/L), WBC white blood count ( $\times 10^9/L$ )



**Acknowledgements** We thank all children and their parents for taking part in our study, as well as all pediatricians and nurses involved in their care, and the staff of the Department of Clinical Chemistry and Laboratory Medicine and technicians of the Institute of Virology at Saarland University Medical Center in Homburg. We thank Eran Eden, Tanya Gottlieb, Lior Kellermann, Amir Nakar, and Eran Reiner (all MeMed) for technical support.

**Author contributions** SM and CP conceived the study and its design, had full access to the data, and take responsibility for the integrity of the data and accuracy of the analysis. Funding acquisition was made by CP. FF, BG, JB, AS, MP, ST, and CP organized and entered data. FF, SM, and CP performed data analyses. All authors contributed to data interpretation. FF and CP wrote the main draft of the manuscript. All authors contributed to the final drafting of the manuscript.

**Funding** Open Access funding enabled and organized by Projekt DEAL. This study has been funded by a 2021 CAREer Grant from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) to CP. Additionally, it was supported by a grant awarded to MeMed from the European Commission, Executive Agency for Small and Medium-sized Enterprises H2020-EIC-SMEInst-2018-2020-2 [grant number 88124]. The funding sources played no role in study design, data collection, data analysis, data interpretation, writing of the manuscript, or in the decision to submit the manuscript for publication.

**Data availability** The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

## Declarations

**Conflict of interest** The authors have no competing interests to declare.

**Ethical approval** This study was approved by the ethical committee of the Ärztekammer des Saarlandes (reference number 019/20).

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

1. Antimicrobial RC. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet*. 2022;399(10325):629–55. [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0).
2. Papan C, Willersinn M, Weiss C, Karremann M, Schrotten H, Tenenbaum T. Antibiotic utilization in hospitalized children under 2 years of age with influenza or respiratory syncytial virus infection - a comparative, retrospective analysis. *BMC Infect Dis*. 2020;20(1):606. <https://doi.org/10.1186/s12879-020-05336-5>.
3. Duong QA, Pittet LF, Curtis N, Zimmermann P. Antibiotic exposure and adverse long-term health outcomes in children: a systematic review and meta-analysis. *J Infect*. 2022. <https://doi.org/10.1016/j.jinf.2022.01.005>.
4. Tegethoff SA, Fröhlich F, Papan C. Point-of-care testing in children with respiratory tract infections and its impact on management and patient flow. *Pediatr Infect Dis J*. 2022;41(11):e475–7. <https://doi.org/10.1097/inf.0000000000003615>.
5. Van den Bruel A, Haj-Hassan T, Thompson M, Buntinx F, Mant D. European Research Network on Recognising Serious Infection i. Diagnostic value of clinical features at presentation to identify serious infection in children in developed countries: a systematic review. *Lancet*. 2010;375(9717):834–45. [https://doi.org/10.1016/S0140-6736\(09\)62000-6](https://doi.org/10.1016/S0140-6736(09)62000-6).
6. Meyer S, Papan C, Last K. A global health perspective on SARS-CoV-2-hazards, disaster and hope. *Wien Med Wochenschr*. 2020;170(13–14):357–8. <https://doi.org/10.1007/s10354-020-00769-8>.
7. Papan C, Last K, Meyer S. COVID-19: fighting the foe with Virchow. *Infection*. 2021;49(5):1069–70. <https://doi.org/10.1007/s15010-021-01628-3>.
8. Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. *Lancet Infect Dis*. 2020;20(11):e276–88. [https://doi.org/10.1016/s1473-3099\(20\)30651-4](https://doi.org/10.1016/s1473-3099(20)30651-4).
9. Ollier Q, Pillet S, Mory O, Gagnaire J, Thuiller C, Annino N, et al. Prospective evaluation of the point-of-care use of a rapid antigenic SARS-CoV-2 immunochromatographic test in a paediatric emergency department. *Clin Microbiol Infect*. 2022;28(5):734. <https://doi.org/10.1016/j.cmi.2021.12.019>.
10. Carlton HC, Savović J, Dawson S, Mitchelmore PJ, Elwenspoek MMC. Novel point-of-care biomarker combination tests to differentiate acute bacterial from viral respiratory tract infections to guide antibiotic prescribing: a systematic review. *Clin Microbiol Infect*. 2021;27(8):1096–108. <https://doi.org/10.1016/j.cmi.2021.05.018>.
11. Scott J, Deresinski S. Use of biomarkers to individualize antimicrobial therapy duration: a narrative review. *Clin Microbiol Infect*. 2022. <https://doi.org/10.1016/j.cmi.2022.08.026>.
12. Papan C, Argentiero A, Porwoll M, Hakim U, Farinelli E, Testa I, et al. A host signature based on TRAIL, IP-10, and CRP for reducing antibiotic overuse in children by differentiating bacterial from viral infections: a prospective, multicentre cohort study. *Clin Microbiol Infect*. 2022;28(5):723–30. <https://doi.org/10.1016/j.cmi.2021.10.019>.
13. Papan C, Argentiero A, Adams O, Porwoll M, Hakim U, Farinelli E, et al. Association of viral load with TRAIL, IP-10, CRP biomarker signature and disease severity in children with respiratory tract infection or fever without source: a prospective, multicentre cohort study. *J Med Virol*. 2023;95(1): e28113. <https://doi.org/10.1002/jmv.28113>.
14. Clark TW, Brendish NJ, Poole S, Naidu VV, Mansbridge C, Norton N, et al. Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19. *J Infect*. 2020;81(4):607–13. <https://doi.org/10.1016/j.jinf.2020.06.051>.
15. Lagi F, Trevisan S, Piccica M, Graziani L, Basile G, Mencarini J, et al. Use of the FebriDx point-of-care test for the exclusion of SARS-CoV-2 diagnosis in a population with acute respiratory infection during the second (COVID-19) wave in Italy. *Int J Infect Dis*. 2021;108:231–6. <https://doi.org/10.1016/j.ijid.2021.04.065>.
16. Tegethoff SA, Danziger G, Kuhn D, Kimmer C, Adams T, Heintz L, et al. TNF-related apoptosis-inducing ligand, interferon gamma-induced protein 10, and C-reactive protein in predicting the progression of SARS-CoV-2 infection: a prospective cohort

- study. *Int J Infect Dis.* 2022;122:178–87. <https://doi.org/10.1016/j.ijid.2022.05.051>.
17. Meyer S, Rissland J, Simon A, Poryo M, Gortner L, Naric J. Multiplex polymerase chain reaction testing in pediatric inpatients with febrile seizures. *J Pediatr.* 2016;179:274–5. <https://doi.org/10.1016/j.jpeds.2016.07.047>.
  18. Oved K, Cohen A, Boico O, Navon R, Friedman T, Etshtein L, et al. A novel host-proteome signature for distinguishing between acute bacterial and viral infections. *PLoS ONE.* 2015;10(3): e0120012. <https://doi.org/10.1371/journal.pone.0120012>.
  19. Van den Bruel A, Thompson MJ, Haj-Hassan T, Stevens R, Moll H, Lakhanpaul M, et al. Diagnostic value of laboratory tests in identifying serious infections in febrile children: systematic review. *BMJ.* 2011;342: d3082. <https://doi.org/10.1136/bmj.d3082>.
  20. Rhedin S, Lundholm C, Horne A, Smew AI, Osvald EC, Haddadi A, et al. Risk factors for multisystem inflammatory syndrome in children - a population-based cohort study of over 2 million children. *Lancet Reg Health Eur.* 2022;19: 100443. <https://doi.org/10.1016/j.lanepe.2022.100443>.
  21. Lam JY, Shimizu C, Tremoulet AH, Bainto E, Roberts SC, Sivilay N, et al. A machine-learning algorithm for diagnosis of multisystem inflammatory syndrome in children and Kawasaki disease in the USA: a retrospective model development and validation study. *Lancet Digit Health.* 2022;4(10):e717–26. [https://doi.org/10.1016/s2589-7500\(22\)00149-2](https://doi.org/10.1016/s2589-7500(22)00149-2).
  22. Sankar J, Garg M, Ghimire JJ, Sankar MJ, Lodha R, Kabra SK. Delayed administration of antibiotics beyond the first hour of recognition is associated with increased mortality rates in children with sepsis/severe sepsis and septic shock. *J Pediatr.* 2021;233:183-90.e3. <https://doi.org/10.1016/j.jpeds.2020.12.035>.
  23. Tan CD, van der Walle E, Vermont CL, von Both U, Carrol ED, Eleftheriou I, et al. Guideline adherence in febrile children below 3 months visiting European Emergency Departments: an observational multicenter study. *Eur J Pediatr.* 2022;181(12):4199–209. <https://doi.org/10.1007/s00431-022-04606-5>.
  24. Borensztajn DM, Hagedoorn NN, Rivero Calle I, Maconochie IK, von Both U, Carrol ED, et al. Variation in hospital admission in febrile children evaluated at the Emergency Department (ED) in Europe: PERFORM, a multicentre prospective observational study. *PLoS ONE.* 2021;16(1): e0244810. <https://doi.org/10.1371/journal.pone.0244810>.